Disease · MONDO_0100280
Trials140
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 20 of 140
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02343120 | Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | Phase 1/2 | 385 | 2022-04-27 | B-cell Malignancies | ZANUBRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01799889 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | Phase 2 | 326 | 2020-09-23 | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Non-FL Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | ENTOSPLETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03053440 | A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) | Phase 3 | 201 | 2023-06-09 | Waldenström's Macroglobulinemia | IBRUTINIB, ZANUBRUTINIB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | Phase 3 | 181 | 2020-11-16 | Waldenström's Macroglobulinemia | IBRUTINIB, RITUXIMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00481871 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | Phase 1/2 | 119 | 2012-09-18 | Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia | GEMCITABINE HYDROCHLORIDE, PRALATREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT02180724 | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | Phase 2 | 107 | 2020-04-24 | Waldenström Macroglobulinemia (WM) | ACALABRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03779113 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Phase 1 | 69 | 2026-02-18 | Non Hodgkin Lymphoma | SOVLEPLENIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00422799 | Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM) | Phase 2 | 63 | 2018-01-26 | Waldenstrom's Macroglobulinemia | BORTEZOMIB, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01614821 | Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia | Phase 2 | 63 | 2020-01-21 | Waldenstrom's Macroglobulinemia | IBRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00718419 | A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma | Phase 2 | 56 | 2020-09-03 | Waldenstrom's Macroglobulinemia, Multiple Myeloma | ENZASTAURIN | Its record names the disease | ClinicalTrials.gov |
| NCT00150462 | Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies | Phase 1 | 48 | 2015-12-03 | Waldenstrom's Macroglobulinemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma | CARFILZOMIB, DEXAMETHASONE | Its record names the disease | ClinicalTrials.gov |
| NCT00492050 | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia | Phase 2 | 46 | 2022-05-04 | Waldenstrom's Macroglobulinemia | BORTEZOMIB, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | Phase 1/2 | 46 | 2021-04-23 | Waldenstrom's Macroglobulinemia | BORTEZOMIB, EVEROLIMUS, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04273139 | Ibrutinib + Venetoclax in Untreated WM | Phase 2 | 45 | 2024-04-23 | Waldenstrom Macroglobulinemia, MYD88 Gene Mutation | IBRUTINIB, VENETOCLAX | Its record names the disease | ClinicalTrials.gov |
| NCT03332173 | Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) | Phase 2 | 44 | 2022-03-08 | Waldenström's Macroglobulinemia (WM) | ZANUBRUTINIB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00936611 | LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | Phase 2 | 39 | 2021-01-28 | Waldenstrom's Macroglobulinemia | PANOBINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00422656 | Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | Phase 2 | 37 | 2012-02-16 | Waldenstrom's Macroglobulinemia | PERIFOSINE | Its record names the disease | ClinicalTrials.gov |
| NCT00811733 | A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia | Phase 2 | 37 | 2012-04-30 | Waldenstrom Macroglobulinaemia | OFATUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00976248 | Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia | Phase 2 | 33 | 2014-06-16 | Waldenstrom's Macroglobulinemia | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT02677324 | Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia | Phase 2 | 33 | 2021-05-11 | Waldenstrom Macroglobulinemia | VENETOCLAX | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100280/trials